Dupnitsa
Dupnitsa
Dupnitsa, Kyustendil, Bulgaria7 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition | Active, not recruiting | Phase 3 | 2026-09-30 | NCT05567796 | |
| A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo | Skin and Connective Tissue Diseases, hypopigmentation of the skin, skin disorder, skin pigmentation disorder, vitiligo | Active, not recruiting | Phase 3 | 2026-09-28 | NCT06163326 | |
| A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | COVID-19, Coronaviridae Infections, Infections, Nidovirales infectious disease, Orthocoronavirinae infectious disease, RNA Virus Infections, lung disorder, pneumonia, respiratory system disorder, respiratory tract infectious disorder, viral infectious disease, viral pneumonia | Recruiting | Phase 3 | 2026-09-25 | NCT06679140 | |
| AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications | Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, type 2 diabetes mellitus | Recruiting | Phase 3 | 2026-09-01 | NCT07797335 | |
| REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels | cardiovascular disorder | Active, not recruiting | Phase 3 | 2026-08-31 | NCT05669755 | |
| A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis | Moderate to Severe Atopic Dermatitis | Active, not recruiting | Phase 2 | 2026-08-21 | NCT06136741 | |
| A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis | Plaque Psoriasis | Active, not recruiting | Phase 3 | 2026-06-02 | NCT06550076 |